<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03813160</url>
  </required_header>
  <id_info>
    <org_study_id>JBT101-DM-002</org_study_id>
    <nct_id>NCT03813160</nct_id>
  </id_info>
  <brief_title>Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis</brief_title>
  <acronym>DETERMINE</acronym>
  <official_title>A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corbus Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corbus Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3 multicenter, double-blind, randomized, placebo-controlled study assessing
      the efficacy and safety of lenabasum for the treatment of dermatomyositis. Approximately 150
      subjects will be enrolled in this study at about 60 sites in North America, Europe, and Asia.
      The planned duration of treatment with study drug is 52 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized to receive lenabasum 20 mg twice per day, lenabasum 5 mg twice
      per day, or placebo twice per day in a 2:1:2 ratio. The primary efficacy outcome at Week 52
      will be Total Improvement Score (TIS), which is a weighted composite measure of improvement
      from baseline in six endpoints: Physician Global Assessment of Disease Activity, Physician
      Assessment of Extramuscular Disease Activity, Patient Global Assessment of Disease Activity,
      Health Assessment Questionnaire (patient-reported disability), Manual Muscle Testing (MMT),
      and muscle enzymes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 17, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of lenabasum compared to placebo as measured by Total Improvement Score (TIS)</measure>
    <time_frame>Week 52</time_frame>
    <description>TIS from IMAC Core Set Measures (CSM) will be calculated following Aggarwal et al (2017) recommendations. Scores are based on a 0 - 100 scale; higher scores indicate better improvement in myositis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo as measured by Mean MMT-8 Score</measure>
    <time_frame>Week 52</time_frame>
    <description>Strength in 8 muscle groups will be assessed on a 0 - 10 point scale; lower score is &quot;weaker&quot; and higher score is &quot;stronger.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo as measured by Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score</measure>
    <time_frame>Week 52</time_frame>
    <description>The CDASI is a validated outcome measure that systematically quantifies cutaneous DM activity. Disease involvement in 15 different anatomical locations is rated using three activity (erythema, scale, erosion/ulceration) and two damage (poikiloderma, calcinosis) measures. The presence and severity of Gottron's papules, periungual changes and alopecia are also captured. Disease activity is scored from 0 to 100; higher scores indicate greater disease severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo as measured by Investigator Global Assessment (IGA) scale of skin activity</measure>
    <time_frame>Week 52</time_frame>
    <description>The IGA is used by the investigator to score overall skin disease on a 0 to 4 scale; higher scores indicate greater skin disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo as measured by Short Form-36 (SF-36) physical functioning domain score</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo as measured by corticosteroid dose</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of lenabasum compared to placebo as measured by Forced Vital Capacity (FVC) % predicted</measure>
    <time_frame>Week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of lenabasum compared to placebo as measured by Adverse Events (AEs) associated with lenabasum treatment</measure>
    <time_frame>From initiation of treatment (Day 1) to end of treatment (Week 52)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of lenabasum compared to placebo as measured by number of subjects who permanently discontinue study product due to AEs probably- or definitely-related to treatment</measure>
    <time_frame>From initiation of treatment (Day 1) to end of treatment (Week 52)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dermatomyositis</condition>
  <arm_group>
    <arm_group_label>Lenabasum 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive lenabasum 20 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenabasum 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive lenabasum 5 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenabasum 20 mg</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Lenabasum 20 mg</arm_group_label>
    <other_name>JBT-101</other_name>
    <other_name>anabasum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenabasum 5 mg</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Lenabasum 5 mg</arm_group_label>
    <other_name>JBT-101</other_name>
    <other_name>anabasum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fulfill one of the following criteria for dermatomyositis:

               1. Bohan and Peter criteria (Bohan and Peter, 1975a; Bohan and Peter 1975b)

               2. ACR/EULAR criteria (Lundberg et al, 2017)

          -  Disease activity/severity fulfills one of the following three criteria:

               1. MDGA ≥ 3 cm (0 - 10 cm Visual Analog Scale [VAS]) and MMT-8 score ≤ 142 (out of
                  150 total possible)

               2. Sum of MDGA, PtGA and EMGA VAS scores is ≥ 10 cm (0-10 cm VAS for each)

               3. MDGA ≥ 3 cm (0-10 cm VAS) and CDASI activity score of &gt; 14

          -  Stable doses of immunosuppressive medications for DM as defined by:

               1. Unchanged dose of oral corticosteroids ≤ 20 mg per day prednisone or equivalent
                  for ≥ 4 weeks before Visit 1

               2. Unchanged dose of immunosuppressive medications other than oral corticosteroids
                  for ≥ 8 weeks before Screening

        Exclusion Criteria:

          -  Unstable DM or DM with end-stage organ involvement at Screening or Visit 1

          -  Significant diseases or conditions other than DM that may influence response to the
             study drug or safety

          -  Any of the following values for laboratory tests at Screening:

               1. A positive pregnancy test (or at Visit 1)

               2. Hemoglobin &lt; 9 g/dL in males and &lt; 8 g/dL in females

               3. Neutrophils &lt; 1.0 × 10^9/L

               4. Platelets &lt; 75 × 10^9/L

               5. Creatinine clearance &lt; 50 mL/min on screening blood test, per the Modification of
                  Diet in Renal Disease Study or in 24 hour urine creatine clearance measurement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victoria P Werth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chester V Oddis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh Department of Medicine/Division of Rheumatology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lindsey Smith</last_name>
    <phone>1-617-963-0707</phone>
    <email>DMpatients@corbuspharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Barbara White, MD</last_name>
    <phone>1-617-977-5077</phone>
    <email>DMphysicians@corbuspharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>HonorHealth Neurology</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Pruitt</last_name>
      <phone>480-587-6147</phone>
      <email>jpruitt@honorhealth.com</email>
    </contact>
    <investigator>
      <last_name>Todd Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Branch</last_name>
      <phone>480-301-9392</phone>
      <email>branch.emily@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Aaron R Mangold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Attune Health Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Fortune</last_name>
      <phone>424-281-3653</phone>
      <email>natalie@attunehealth.com</email>
    </contact>
    <investigator>
      <last_name>Swamy Venuturupalli, MD, FACR</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Arshad</last_name>
      <phone>858-246-2389</phone>
      <email>aiarshad@health.ucsd.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Kalunian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Perez</last_name>
      <phone>310-794-2468</phone>
      <email>jsperez@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Volkmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Hernandez</last_name>
      <phone>303-394-2828</phone>
      <phone_ext>177</phone_ext>
      <email>THernandez@DACdenver.com</email>
    </contact>
    <investigator>
      <last_name>Christopher R Antolini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnieszka Zaleski</last_name>
      <phone>203-785-6631</phone>
      <email>agnieszka.zaleski@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Fotios Koumpouras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabrina Elliott</last_name>
      <phone>202-444-6210</phone>
      <email>Se510@georgetown.edu</email>
    </contact>
    <investigator>
      <last_name>Virginia Steen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jany Paulett, CCRC</last_name>
      <phone>904-953-6912</phone>
      <email>paulett.jany@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Jaimin Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethly Aubourg</last_name>
      <phone>305-243-8567</phone>
      <email>baubourg@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Eric L Greidinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Lewis, RN</last_name>
      <phone>813-974-9509</phone>
      <email>glewis@health.usf.edu</email>
    </contact>
    <investigator>
      <last_name>John D. Carter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Aren</last_name>
      <phone>312-503-1824</phone>
      <email>kathleen.aren@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Christine Hsieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Colgan</last_name>
      <phone>913-945-9938</phone>
      <email>scolgan@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Mazen Dimachkie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DelRicht Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josh Taylor</last_name>
      <phone>504-336-2667</phone>
      <email>jtaylor@delricht.com</email>
    </contact>
    <investigator>
      <last_name>Lesley Saketkoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grazyna Purwin</last_name>
      <phone>410-550-3609</phone>
      <email>gpurwin1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Lisa Christopher-Stine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Anderson</last_name>
      <phone>734-998-1271</phone>
      <email>staceaan@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Elena Schiopu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, Division of Rheumatic and Autoimmune Diseases</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mandi DeGrote</last_name>
      <phone>612-626-7609</phone>
      <email>carl1032@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Jerry Molitor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Bruns</last_name>
      <phone>314-747-5366</phone>
      <email>brunsj@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Heather Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU School of Medicine; The Ronald O. Perelman Dept. of Dermatology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Cataldo</last_name>
      <phone>212-263-5244</phone>
      <email>susan.cataldo@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Alisa N. Femia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liza Morales</last_name>
      <phone>212-774-2561</phone>
      <email>moralesli@HSS.EDU</email>
    </contact>
    <investigator>
      <last_name>David Fernandez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Doyle</last_name>
      <phone>216-636-1196</phone>
      <email>Doyleb4@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Anthony Fernandez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Concha, MD</last_name>
      <phone>215-615-2940</phone>
      <email>Josef.Concha@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Victoria P Werth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh, Division of Rheumatology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Koontz</last_name>
      <phone>412-383-8671</phone>
      <email>dik4@pitt.edu</email>
    </contact>
    <investigator>
      <last_name>Chester V. Oddis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUSC: Department of Neurology</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aparna Choudhury</last_name>
      <phone>843-792-2845</phone>
      <email>choudhur@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Ruzhansky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Neuromuscular Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nawar Hussin</last_name>
      <phone>512-920-0140</phone>
      <email>nawar@austinneuromuscle.com</email>
    </contact>
    <investigator>
      <last_name>Yessar Hussain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rheumatic Disease Center</name>
      <address>
        <city>Glendale</city>
        <state>Wisconsin</state>
        <zip>53217</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Kritter</last_name>
      <phone>414-351-4009</phone>
      <phone_ext>38</phone_ext>
      <email>lynn.kritter@rdcwi.com</email>
    </contact>
    <investigator>
      <last_name>Mary E Cronin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital &quot;Kaspela&quot; Rheumatology Clinic</name>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anastas Batalov, MD, PhD</last_name>
      <phone>+359 32 602273</phone>
      <email>abatalov@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mobile</last_name>
      <phone>+359 888 370497</phone>
    </contact_backup>
    <investigator>
      <last_name>Anastas Batalov, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;St. Ivan Rilski&quot;</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Zlatimir Kolarov, MD</last_name>
      <phone>359888220118</phone>
      <email>zkolarov@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Prof. Zlatimir Kolarov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMHAT</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanya Aleksieva-Petkova</last_name>
      <phone>00359898979821</phone>
      <email>dr.tanya.aleksieva@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tanya Aleksieva-Petkova</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, Dept. of Dermatology and Skin Science</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaspal Mor</last_name>
      <phone>604-875-5296</phone>
      <email>jaspal.mor@ubc.ca</email>
    </contact>
    <investigator>
      <last_name>Jan Dutz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Revmatologicky ustav</name>
      <address>
        <city>Prague</city>
        <zip>12850</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiri Vencovsky, MD, DSc.</last_name>
      <email>vencovsky@revma.cz</email>
    </contact>
    <investigator>
      <last_name>Jiri Vencovsky, MD, DSc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite-Universitatsmedizin, Division of Rheumatology and Clinical Immunology</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Zernicke</last_name>
      <phone>+4930450613025</phone>
      <email>jan.zernicke@charite.de</email>
    </contact>
    <investigator>
      <last_name>Udo Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charite-Universitatsmedizin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margitta Worm, Prof</last_name>
      <phone>+4930450518105</phone>
      <email>Margitta.Worm@charite.de</email>
    </contact>
    <investigator>
      <last_name>Margitta Worm, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Erlangen Nuremberg</name>
      <address>
        <city>Erlangen</city>
        <zip>D- 91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jörg Distler, Prof</last_name>
      <phone>+49-9131-8543014</phone>
      <email>joerg.distler@uk-erlangen.de</email>
    </contact>
    <investigator>
      <last_name>Jörg Distler, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Goettingen</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Schmidt, Prof</last_name>
      <phone>+49-551-39-9293</phone>
      <email>j.schmidt@med.uni-goettingen.de</email>
    </contact>
    <investigator>
      <last_name>Jens Schmidt, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Debrecen</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anett Vincze</last_name>
      <phone>36307178948</phone>
      <email>anett.vincze93@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Katalin Dankó, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Rheumatology and Immunology, Clinical Centre, University of Pecs</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Varju, MD, PhD</last_name>
      <phone>+36-72-536-802</phone>
      <email>varju.cecilia@pte.hu</email>
    </contact>
    <contact_backup>
      <phone>+36-30-213-4820</phone>
      <email>cecilia.varju@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Cecilia Varju, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Policlinico-Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>95121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario Foti</last_name>
      <email>rosfoti5@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rosario Foti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pisa University Hospital - Santa Chiara Hospital, Reumatology Unit</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Barsotti</last_name>
      <phone>+390502210625</phone>
      <email>Simone.barsotti.pisa@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Marta Mosca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario A.Gemelli-IRCCS</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisa Gremese</last_name>
      <email>elisa.gremese@policlinicogemelli.it</email>
    </contact>
    <investigator>
      <last_name>Elisa Gremese</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gunma University Hospital</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hokkaido University Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Miyagi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nagasaki University Hospital</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Keio University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical Hospital</name>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>YeRa Jo</last_name>
      <email>parkwon@inha.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Won Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Jo Eun</last_name>
      <email>ysong@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yeong-Wook Song</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun Jung Kim</last_name>
      <email>dhyoo@hanyang.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Dae-Hyun Yoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chang Ae Moon</last_name>
      <phone>82-2-2258-2034</phone>
      <email>cmoon0317@naver.com</email>
    </contact>
    <investigator>
      <last_name>Ji Hyeon Ju</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KLIMED</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karolina Bagnowska</last_name>
      <phone>+48 882 709 710</phone>
      <email>karolina.bagnowska@wp.pl</email>
    </contact>
    <contact_backup>
      <last_name>Marek Klimkiewicz</last_name>
      <email>badanie3@onet.pl</email>
    </contact_backup>
    <investigator>
      <last_name>Krystyna Kuc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRMED</name>
      <address>
        <city>Piotrków Trybunalski</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Klimkiewicz</last_name>
      <phone>+48 605 908 809</phone>
      <email>iwona.klimkiewicz@ir-med.pl</email>
    </contact>
    <investigator>
      <last_name>Agnieszka Walkowiak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kliniczny Szpital Wojewodzki Nr 1. im Fryderyka Chopina Klinika Dermatologii</name>
      <address>
        <city>Rzeszow</city>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Reich</last_name>
      <email>adamandrzejreich@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Adam Reich</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institute of Geriatrics, Rheumatology and Rehabilitation</name>
      <address>
        <city>Warsaw</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marzena Olesinska</last_name>
      <email>marzena.olesinska@vp.pl</email>
    </contact>
    <investigator>
      <last_name>Marzena Olesinska</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>KLIMED</name>
      <address>
        <city>Łomża</city>
        <zip>18-404</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marek Klimkiewicz</last_name>
      <phone>+48 603 157 778</phone>
      <email>badanie3@onet.pl</email>
    </contact>
    <investigator>
      <last_name>Wojciech Bakowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron General Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Selva-O'Callaghan</last_name>
      <email>eselva@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Albert Selva-O'Callaghan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital 12 Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paloma Jimenez</last_name>
    </contact>
    <investigator>
      <last_name>Patricia Carreira</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital, Rheumatology Clinic</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Lundberg</last_name>
      <phone>+46 73 53 76 921</phone>
      <email>ingrid.lundberg@ki.se</email>
    </contact>
    <investigator>
      <last_name>Ingrid Lundberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinik für Rheumatologie</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Rubbert-Roth</last_name>
    </contact>
    <investigator>
      <last_name>Andrea Rubbert-Roth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>King's College Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Gordon</last_name>
      <email>patrick.gordon2@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Patrick Gordon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hector Chinoy</last_name>
      <email>Hector.Chinoy@srft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Hector Chinoy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 21, 2019</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dermatomyositis</keyword>
  <keyword>cannabinoid receptor type 2 agonist</keyword>
  <keyword>JBT-101</keyword>
  <keyword>lenabasum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatomyositis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

